Comparison
AGP Limited vs GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited (GLAXO) is worth Rs 99.4 bn at the latest close, 2.2 times the market value of AGP Limited (AGP) at Rs 45.5 bn. In their latest annual results AGP reported revenue of Rs 28.9 bn (FY2025) and GLAXO Rs 65.9 bn (FY2025). AGP trades at 12.2× earnings and GLAXO at 9.5×. Dividend yields: AGP 4.9%, GLAXO 5.4%.
| Latest | AGP FY2025 | GLAXO FY2025 |
|---|---|---|
| Price | Rs 162.48 | Rs 312.07 |
| Market value | Rs 45.5 bn | Rs 99.4 bn |
| P/E | 12.2× | 9.5× (stronger) |
| P/B | 3.03× | 2.89× (stronger) |
| Dividend yield | 4.9% | 5.4% (stronger) |
| Revenue (latest year) | Rs 28.9 bn | Rs 65.9 bn |
| Revenue growth, year on year | 15.4% (stronger) | 7.7% |
| Revenue growth, 5 years a year | 33.0% (stronger) | 13.4% |
| Profit (latest year) | Rs 3.7 bn | Rs 10.0 bn (stronger) |
| EPS (latest year) | Rs 13.34 | Rs 31.48 |
| Dividend per share | Rs 8.00 | Rs 17.00 |
| Net margin | 15.0% | 15.2% (stronger) |
| Return on equity | 25.9% | 32.4% (stronger) |
| Debt to equity | 59.1% | 1.1% (stronger) |
| Current ratio | 1.01× | 2.32× (stronger) |
| Dividend streak (years) | 8 (stronger) | 2 |
Highlighted: the higher figure where higher is usually stronger (growth, margins, returns, yield) or the lower where lower is (P/E, P/B, debt). A highlight is a comparison, not a recommendation.
AGP
AGP Limited financial statements →
GLAXO
GlaxoSmithKline Pakistan Limited financial statements →
Related comparisons
Prices at the latest close; financial figures from each company's latest annual report. Information only, not investment advice.